News

In addition, the two entities have also signed an exclusive distribution agreement for the commercialisation of Daxas in the UK. As per the terms of the agreement, Nycomed

Charles River Laboratories International is a global provider of research models and associated services and of preclinical drug development services, while WuXi PharmaTech (Cayman) is a drug research

Transposagen Biopharmaceuticals said academic, pharmaceutical, and biotech scientists use these animals for drug discovery and development research and are expected to be sold under its new TGEM Rat

UCB said that FDA’s response is to an NDA Supplement, which was submitted by the company in June 2009, with a proposal for new refrigerated storage conditions to

The modified Regenesis Phase IIb trial is a placebo controlled, double blinded, 3:1 randomised clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January

The joint venture represents a new opportunity for both companies to expand their business in the pharmaceutical market in China. As per the terms of the agreement, Macfarlan

Shire said that the lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Teva for generic versions of 1mg, 2mg, 3mg and 4mg guanfacine hydrochloride extended

Symphogen believes Sympress II technology could supply drug product for large indications such as cancer and infectious disease. The Sympress II results demonstrated single-batch production of compositions with

Reportedly, the entire facility is spread across 5000 sqft for formulation, development and analytical development and is designed and equipped to meet the stringent international standards. Bafna Pharmaceuticals